Table of Contents Author Guidelines Submit a Manuscript
BioMed Research International
Volume 2015 (2015), Article ID 419383, 10 pages
http://dx.doi.org/10.1155/2015/419383
Research Article

A Novel Microbisporicin Producer Identified by Early Dereplication during Lantibiotic Screening

1Fondazione Istituto Insubrico Ricerca per la Vita (F.I.I.R.V.), Via R. Lepetit 32, 21100 Gerenzano, Italy
2Dipartimento di Biotecnologie e Scienze della Vita, Università degli Studi dell’Insubria, Via J. H. Dunant 3, 21100 Varese, Italy
3“The Protein Factory” Research Center, Politecnico of Milano, ICRM CNR Milano and University of Insubria, Via J. H. Dunant 3, 21100 Varese, Italy

Received 30 January 2015; Revised 29 May 2015; Accepted 31 May 2015

Academic Editor: Paul M. Tulkens

Copyright © 2015 Lucia Carrano et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. P. J. Knerr and W. A. van der Donk, “Discovery, biosynthesis and engineering of lantipeptides,” Annual Review of Biochemistry, vol. 81, pp. 479–505, 2012. View at Publisher · View at Google Scholar · View at Scopus
  2. P. G. Arnison, M. J. Bibb, G. Bierbaum et al., “Ribosomally synthesized and post-translationally modified peptide natural products: overview and recommendations for an universal nomenclature,” Natural Product Reports, vol. 30, pp. 108–160, 2013. View at Google Scholar
  3. J. Lubelski, R. Rink, R. Khusainov, G. N. Moll, and O. P. Kuipers, “Biosynthesis, immunity, regulation, mode of action and engineering of the model lantibiotic nisin,” Cellular and Molecular Life Sciences, vol. 65, no. 3, pp. 455–476, 2008. View at Publisher · View at Google Scholar · View at Scopus
  4. P. D. Cotter, C. Hill, and R. P. Ross, “Bacterial lantibiotics: strategies to improve therapeutic potential,” Current Protein and Peptide Science, vol. 6, no. 1, pp. 61–75, 2005. View at Publisher · View at Google Scholar · View at Scopus
  5. S. Somma, W. Merati, and F. Parenti, “Gardimycin, a new antibiotic inhibiting peptidoglycan synthesis,” Antimicrobial Agents and Chemotherapy, vol. 11, no. 3, pp. 396–401, 1977. View at Publisher · View at Google Scholar · View at Scopus
  6. H. Brötz, G. Bierbaum, P. E. Reynolds, and H.-G. Sahl, “The lantibiotic mersacidin inhibits peptidoglycan biosynthesis at the level of transglycosylation,” European Journal of Biochemistry, vol. 246, no. 1, pp. 193–199, 1997. View at Publisher · View at Google Scholar · View at Scopus
  7. F. Castiglione, L. Cavaletti, D. Losi et al., “A novel lantibiotic acting on bacterial cell wall synthesis produced by the uncommon actinomycete Planomonospora sp.,” Biochemistry, vol. 46, no. 20, pp. 5884–5895, 2007. View at Publisher · View at Google Scholar · View at Scopus
  8. F. Castiglione, A. Lazzarini, L. Carrano et al., “Determining the structure and mode of action of microbisporicin, a potent lantibiotic active against multiresistant pathogens,” Chemistry and Biology, vol. 15, no. 1, pp. 22–31, 2008. View at Publisher · View at Google Scholar · View at Scopus
  9. S. Jovetic, Y. Zhu, G. L. Marcone, F. Marinelli, and J. Tramper, “β-Lactam and glycopeptide antibiotics: first and last line of defense?” Trends in Biotechnology, vol. 28, no. 12, pp. 596–604, 2010. View at Publisher · View at Google Scholar · View at Scopus
  10. H. E. Hasper, N. E. Kramer, J. L. Smith et al., “An alternative bactericidal mechanism of action for lantibiotic peptides that target lipid II,” Science, vol. 313, no. 5793, pp. 1636–1637, 2006. View at Publisher · View at Google Scholar · View at Scopus
  11. H. Brötz, G. Bierbaum, K. Leopold, P. E. Reynolds, and H.-G. Sahl, “The lantibiotic mersacidin inhibits peptidoglycan synthesis by targeting lipid II,” Antimicrobial Agents and Chemotherapy, vol. 42, no. 1, pp. 154–160, 1998. View at Google Scholar · View at Scopus
  12. A. J. Lepak, K. Marchillo, W. A. Craig, and D. R. Andes, “In vivo pharmacokinetics and pharmacodynamics of the lantibiotic NAI-107 in a neutropenic murine thigh infection model,” Antimicrobial Agents and Chemotherapy, vol. 59, no. 2, pp. 1258–1264, 2015. View at Publisher · View at Google Scholar
  13. D. Jabés, C. Brunati, G. Candiani, S. Riva, G. Romanó, and S. Donadio, “Efficacy of the new lantibiotic NAI-107 in experimental infections induced by multidrug-resistant gram-positive pathogens,” Antimicrobial Agents and Chemotherapy, vol. 55, no. 4, pp. 1671–1676, 2011. View at Publisher · View at Google Scholar · View at Scopus
  14. A. B. Tabor, “Recent advances in synthetic analogues of lantibiotics: what can we learn from these?” Bioorganic Chemistry, vol. 55, pp. 39–50, 2014. View at Publisher · View at Google Scholar · View at Scopus
  15. J. Cortes, A. N. Appleyard, and M. J. Dawson, “Whole-cell generation of lantibiotic variants,” Methods in Enzymology, vol. 458, pp. 559–574, 2009. View at Google Scholar
  16. J.-I. Nagao, M. Nishie, and K. Sonomoto, “Methodologies and strategies for the bioengineering of lantibiotics,” Current Pharmaceutical Biotechnology, vol. 12, no. 8, pp. 1221–1230, 2011. View at Publisher · View at Google Scholar · View at Scopus
  17. Y. Shi, A. Bueno, and W. A. van der Donk, “Heterologous production of the lantibiotic Ala(0)actagardine in Escherichia coli,” Chemical Communications, vol. 48, no. 89, pp. 10966–10968, 2012. View at Publisher · View at Google Scholar · View at Scopus
  18. S. I. Maffioli, P. Monciardini, B. Catacchio et al., “Family of class I lantibiotics from actinomycetes and improvement of their antibacterial activities,” ACS Chemical Biology, vol. 10, no. 4, pp. 1034–1042, 2015. View at Publisher · View at Google Scholar
  19. V. Fedorenko, O. Genilloud, L. Horbal et al., “Antibacterial discovery and development: from gene to product and back,” BioMed Research International. In press.
  20. F. Marinelli, “From microbial products to novel drugs that target a multitude of disease indications,” Methods in Enzymology, vol. 458, pp. 29–58, 2009. View at Publisher · View at Google Scholar · View at Scopus
  21. R. H. Baltz, “Renaissance in antibacterial discovery from actinomycetes,” Current Opinion in Pharmacology, vol. 8, no. 5, pp. 557–563, 2008. View at Publisher · View at Google Scholar · View at Scopus
  22. F. E. Koehn, “High impact technologies for natural products screening,” Progress in Drug Research, vol. 65, pp. 175, 177–210, 2008. View at Google Scholar
  23. T. Tamura, Y. Ishida, Y. Nozawa, M. Otoguro, and K.-I. Suzuki, “Transfer of Actinomadura spadix Nonomura and Ohara 1971 to Actinoallomurus spadix gen. nov., comb. nov., and description of Actinoallomurus amamiensis sp. nov., Actinoallomurus caesius sp. nov., Actinoallomurus coprocola sp. nov., Actinoallomurus fulvus sp. nov., Actinoallomurus iriomotensis sp. nov., Actinoallomurus luridus sp. nov,” International Journal of Systematic and Evolutionary Microbiology, vol. 59, no. 8, pp. 1867–1874, 2009. View at Publisher · View at Google Scholar · View at Scopus
  24. R. Pozzi, M. Simone, C. Mazzetti et al., “The genus Actinoallomurus and some of its metabolites,” Journal of Antibiotics, vol. 64, no. 1, pp. 133–139, 2011. View at Publisher · View at Google Scholar · View at Scopus
  25. C. Mazzetti, M. Ornaghi, E. Gaspari et al., “Halogenated spirotetronates from Actinoallomurus,” Journal of Natural Products, vol. 75, no. 6, pp. 1044–1050, 2012. View at Publisher · View at Google Scholar · View at Scopus
  26. R. E. O. Williams, “L-forms of Staphylococcus aureus,” Journal of General Microbiology, vol. 33, pp. 325–334, 1963. View at Publisher · View at Google Scholar · View at Scopus
  27. NCCLS, Approved Standard M7-A2. Methods for Dilution Antimicrobial Susceptibility Testing for Bacteria That Grow Anaerobically, Villanova University, Villanova, Pa, USA, 1990.
  28. A. Lazzarini, L. Cavaletti, G. Toppo, and F. Marinelli, “Rare genera of actinomycetes as potential producers of new antibiotics,” Antonie van Leeuwenhoek, vol. 79, no. 3-4, pp. 399–405, 2001. View at Google Scholar · View at Scopus
  29. P. Monciardini, M. Sosio, L. Cavaletti, C. Chiocchini, and S. Donadio, “New PCR primers for the selective amplification of 16S rDNA from different groups of actinomycetes,” FEMS Microbiology Ecology, vol. 42, no. 3, pp. 419–429, 2002. View at Publisher · View at Google Scholar · View at Scopus
  30. T. A. Hall, “BioEdit: a user-friendly biological sequence alignment editor and analysis program for Windows 95/98/NT,” Nucleic Acids Symposium Series, vol. 51, pp. 95–98, 1999. View at Google Scholar
  31. S. I. Maffioli, M. Iorio, M. Sosio, P. Monciardini, E. Gaspari, and S. Donadio, “Characterization of the congeners in the lantibiotic NAI-107 complex,” Journal of Natural Products, vol. 77, no. 1, pp. 79–84, 2014. View at Publisher · View at Google Scholar · View at Scopus
  32. M. D. Lee, US patent 6,551,591, 2003.
  33. L. C. Foulston and M. J. Bibb, “Microbisporicin gene cluster reveals unusual features of lantibiotic biosynthesis in actinomycetes,” Proceedings of the National Academy of Sciences of the United States of America, vol. 107, no. 30, pp. 13461–13466, 2010. View at Publisher · View at Google Scholar · View at Scopus
  34. E. J. Sherwood, A. R. Hesketh, and M. J. Bibb, “Cloning and analysis of the planosporicin lantibiotic biosynthetic gene cluster of Planomonospora alba,” Journal of Bacteriology, vol. 195, no. 10, pp. 2309–2321, 2013. View at Publisher · View at Google Scholar · View at Scopus
  35. V. Arioli, M. Berti, and L. G. Silvestri, “Gardimycin, a new antibiotic from Actinoplanes. III. Biological properties,” Journal of Antibiotics, vol. 29, no. 5, pp. 511–515, 1976. View at Publisher · View at Google Scholar · View at Scopus
  36. L. Carrano and F. Marinelli, “The relevance of chemical dereplication in microbial natural product screening,” Journal of Applied Bioanalysis, vol. 1, no. 2, pp. 55–67, 2015. View at Publisher · View at Google Scholar